# THE USE OF CYA AND ALLOGRAFTS IN RECONSTRUCTIVE SURGERY

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA-IRVINE · 1988 · $153,495

## Abstract

The successful transplantation of vascularized limbs or even
other vascularized blocks of tissue (composite tissue allograft
modules; CTA) would have profound implications in
reconstructive surgery.  CTAs or substructures thereof would be
useful for constructing severe musculoskeletal defects.  The
final goal of these studies is to lay the experimental foundation
for the ultimate clinical exploitation of CyA and CTAs.  The rat
hind limb serves as an excellent vascularized model of a CTA
composed of skin, subsutaneous fat, muscle, synovial joints,
bone, bone-marrow, and neurovascular structures.  The rat limb
offers a unique model to study each individual tissue within a
well defined histocompatibility system.  We have established the
first principle necessary for the contemplation of utilizing CTAs
combined with cyclosporine clinically: namely, that a minimal
CyA dose is effective for preventing rejection (1). Secondly, we
have also established that composite tissue allografts
transplanted across this major histocompatibility barrier can
demonstrated indefinite survival with moderate doses of
cyclosporine with no inherent toxicity (2). Thus, we believe that
the clinical potential for CTAs is even more promising today
than we had originally envisioned.  We intend to further study
methods aimed at achieving indefinite or long-term allograft
survival in combination with the use of CyA.  The immune status
of long-term surviving, chimeric, and apparently tolerant CTA
recipients (2,3) will be characterized.  Unique rejection
processes will be further delineated histothologically.  A new
dose-response curve will be established across a much stronger
histocompability barrier (ACI-greater than LEW; Rt-1 a-greater
than 1) to convincingly confirm cyclosporine's potential for
preventing CTA rejection at relatively low doses.  We propose to
characterizing the possible development of lymphoid chimerism
and thus potential graft versus host disease in this strong fully
allogeneic CTA model with sensitive fluorescence activated cell
sorter analysis.

## Key facts

- **NIH application ID:** 3156246
- **Project number:** 5R01AR032263-05
- **Recipient organization:** UNIVERSITY OF CALIFORNIA-IRVINE
- **SAM.gov UEI:** MJC5FCYQTPE6
- **Principal Investigator:** BRUCE M ACHAUER
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1988
- **Award amount:** $153,495
- **Award type:** 5
- **Project period:** 1983-12-01 → 1989-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3156246

## Citation

> US National Institutes of Health, RePORTER application 3156246, THE USE OF CYA AND ALLOGRAFTS IN RECONSTRUCTIVE SURGERY (5R01AR032263-05). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3156246. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*